Evidence map›Paper›PMID 41541671›Full record

ArticleiScience2026

TMT1A inhibits lung adenocarcinoma progression by suppressing M2 macrophage polarization.

Junfan Pan, Qiongwen Wu, Yunan Zhao, Sixuan Wu, Liu He, Qihong Pan, Xiaohui Chen, Jing Zhang, Yiquan Xu

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Junfan PanClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Qiongwen WuSchool of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China.
Yunan ZhaoFuzhou University Affiliated Provincial Hospital, Fuzhou 350001, China.
Sixuan WuClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Liu HeSchool of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China.
Qihong PanClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Xiaohui ChenDepartment of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, NHC Key Laboratory of Cancer Metabolism, Fuzhou 350014, China.
Jing ZhangClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Yiquan XuClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of thiol methyltransferase 1A (TMT1A) in lung adenocarcinoma (LUAD) progression and the immune microenvironment remains unclear. Analysis of clinical samples and public databases revealed significantly lower TMT1A expression in tumorous LUAD samples compared to non-neoplastic counterparts. Cox regression analysis confirmed TMT1A as an independent prognostic factor for LUAD. Phenotypically, functional assays demonstrated that

Indexed as

cancerimmunology

Identifiers

PMID41541671
PMCPMC12799785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.